Targeting TNF superfamily members for therapeutic intervention in rheumatoid arthritis

Cytokine

Volumn 57, Issue 3, 2012, Pages 305-312

  Vinay, Dass S ^a   Kwon, Byoung S ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b National Cancer Center   (South Korea)

Author keywords

B cells; Rheumatoid arthritis; T cells; Therapy; Tumor necrosis factor superfamily

Indexed keywords

ADALIMUMAB; ATACICEPT; AUTOANTIBODY; BELIMUMAB; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CD30 LIGAND; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD70 ANTIGEN; CERTOLIZUMAB PEGOL; DEATH RECEPTOR 5; ETANERCEPT; FC RECEPTOR; FLOXURIDINE; GOLIMUMAB; INFLIXIMAB; LIPOSOME; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; DRUG TARGETING; EPIGASTRIC DISCOMFORT; HODGKIN DISEASE; HUMAN; IMMUNOREGULATION; JOINT DESTRUCTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM;

ANTIGENS, CD; ARTHRITIS, RHEUMATOID; HUMANS; MOLECULAR TARGETED THERAPY; TUMOR NECROSIS FACTORS;

EID: 84856378337     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.12.005     Document Type: Review

References (160)

1. Harris E.D. Rheumatoid arthritis: pathophysiology and implications in therapy. New Eng J Med 1990, 322:1277-1289.
2. Zvaifler N.J. Pathogenesis of the joint disease of rheumatoid arthritis. Am J Med 1983, 75:3-8.
3. Schuna A.A. Update on treatment of rheumatoid arthritis. J Am Pharm Assoc [Washington DC] 1998, 38:728-735.
4. + T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 1998, 41:1669-1676.
5. Lubberts E., Joosten L.A., Oppers B., van den Bersselaar L., Coenen-de Roo C.J., Kolls J.K., et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
6. Koenders M.I., Joosten L.A., van den Berg W.B. Potential new targets in arthritis therapy: interleukin [IL] -17 and its relation to tumor necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006, 65:iii29-iii33.
7. Bush K.A., Farmer K.M., Walker J.S., Kirkham B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with IL-17 receptor IgG, Fc fusion protein. Arthritis Rheum 2002, 46:802-805.
8. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
9. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immnuol 2003, 171:6173-6177.
10. Takemura S., Klimiuk P.A., Braun A., Gornozy J.J., Weyand C.M. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2010, 167:4710-4718.
11. Silverman G.J., Carson D.A. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003, 5:S1-S6.
12. Roll P., Dorner T., Tony H.P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008, 58:1566-1575.
13. Grewal I.S. Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv Exp Med Biol 2009, 647:1-7.
14. Hsu H.C., Wu Y., Mountz J.D. Tumor necrosis factor ligand-receptor superfamily and arthritis. Apoptosis and relevance to autoimmunity 2006, 37-54. Karger, Basel, Switzerland. K. Elkon (Ed.).
15. Tansey M.G., Szymkowski D.E. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Disc Today 2009, 14:1082-1088.
16. Vinay D.S., Kwon B.S. The tumor necrosis factor/TNF receptor superfamily: therapeutictargets in autoimmune diseases. Clin Exp Immunol 2011, 162:145-157.
17. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 36:675-681.
18. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Bijlsma J.W., et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005, 64:iv2-iv14.
19. Smolen J.S., Han C., Bala M., Maini R.N., Kalden J.R., van der Heijde D., et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005, 52:1020-1030.
20. Smolen J.S., Aletaha D. Developments in the clinical understanding of rheumatoid arthritis. Arthritis Res Ther. 2009, 11:204.
21. Borst J., Hendriks J., Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005, 17:275-281.
22. Lens S.M., Baars P.A., Hooibrink B., van Oers M.H., van Lier R.A. Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells. Immunology 1997, 90:38-45.
23. Laouar A., Haridas V., Vargas D., Chaplin D., van Lier R.A., Manjunath N. CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat Immunol 2005, 6:698-706.
24. Hendriks J., Gravestein L.A., Tesselar K., van Lier R.A., Schumacher T.N., Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000, 1:433-440.
25. Kobata T., Jacquot S., Kozlowski S., Agematsu K., Schlossman S.F., Morimoto C. CD27-CD70 interactions regulate B-cell activity by T cells. Proc Nat Acad Sci USA 1995, 92:11249-11253.
26. h1 cell development. Int Immunol 2007, 19:713-718.
27. Agematsu K., Nagumo H., Oguchi Y., Nakazawa T., Fukushima K., Yasui K., et al. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood 1998, 19:173-180.
28. Jacquot S., Kobata T., Iwata S., Iwata S., Morimoto C., Schlossman S.F. CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling. J Immunol 1997, 159:2652-2657.
29. Nagumo H., Agematsu K., Shinozaki K., Hokibara S., Ito S., Takamoto M., et al. CD27/CD70 interaction augments IgE secretion by promoting the differentiation of memory B cells into plasma cells. J Immunol 1998, 161:6492-6502.
30. Oflazoglu E., Boursalian T.E., Zeng W., Edawrds A.C., Duniho S., McEarchem J.A., et al. Blocking CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. J Immunol 2009, 183:3770-3777.
31. Lee W.W., Yang Z.Z., Li G., Weyand C.M., Goronzy J.J. Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J Immunol 2007, 179:2609-2615.
32. Corcione A., Ferlito F., Gotorno M., Gregorio A., Pistorio A., Gastaldi R., et al. Arthritis Res Ther 2009, 11:R150.
33. Moller B., Aeberli D., Eggli S., Fuhrer M., Vajtai I., Vogelin E., et al. Arthritis Res Ther 2009, 11:R62.
34. Schwab U., Stein H., Gerdes J., Lemke H., Kirchner H., Schaadt M., et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982, 299:65-67.
35. Annunziato F, Romagnani P, Mavilia C, Pizzolo G, Stein H, Romagnani S. In: Durum SK, Hirano T, Vilcek J, Nicola NA, editors, Cytokine reference. UK: Acad Press; 2000. p. 1669-84.
36. Smith C.A., Gruss H.J., Davis T., Anderson D., Farrah T., Baker E., et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993, 73:1349-1360.
37. Hansen H.P., Kisseleva T., Kobarg J., Horn-Lohrens O., Havsteen B., Lemke H. A zinc metallopreoteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 1995, 63:750-756.
38. Carvalho R.F., Ulfgren A.K., Engstrom M., Klint E., Nisson G. CD153 in rheumatoid arthritis: detection of soluble form in serum and synovial fluid, and expression by mast cells in the rheumatic synovium. J Rheumatol 2009, 36:501-517.
39. Gerli R., Muscat C., Bistoni O., Falini B., Tomassini C., Agea E., et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis [RA] are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995, 102:547-550.
40. Okamoto A., Yamamura M., Iwahashi M., Aita I., Ueno A., Kawashima M., et al. Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. Acta Med Okayama 2003, 57:267-277.
41. Schlaf G., Altermann W.W., Rothhoff A., Seliger B. Soluble CD30 serum level-an adequate marker for allograft rejection of solid organs?. Histol Histopathol 2007, 22:1269-1279.
42. Gerli R., Pitzalis C., Bistoni O., Falinio B., Costantini V., Russano A., et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J. Immunol 2000, 164:4399-4407.
43. Callan M.F. Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients. Curr Opin Rheumatol 2004, 16:399-405.
44. Kikuchi K., Miyazaki Y., Tanaka A., Shigematu H., Kojima M., Sakashita H., et al. Methotrexate-related Expstein-Barr virus [EBV] -associated lymphoproliferative disorder-so-called " Hodgkin-like lesion" -of the oral cavity in a patient with rheumatoid arthritis. Head Neck Pathol 2010, 4:305-311.
45. Takei M., Kang H., Tomura K., Ikeda E., Karasaki M., Nakauchi H., et al. Expression of Leu M1 antigen on a monoclonal B cell line established from a patient with rheumatoid arthritis. Immunol Lett 1989, 23:43-47.
46. Satoh K., Yoshida N., Imaizumi K., Yazima M., Wakui H., Sawada K., et al. Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis. Am J Med Sci 2009, 338:334-335.
47. Ong C., Sullivan J., Hertzberg M., Stapleton K. Stage IV CD30+ anaplastic large cell lymphoma: response to acitretin and interferon-α. Australasian J Dermatol 2002, 43:207-210.
48. Parker S.R., Solomon A.R., Lane J.E. A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma. J Am Acad Dermatol 2008, 59:157-161.
49. Pfistershammer K., Petzelbauer P., Stingl G., Mastan P., Chott A., Jager U., et al. Methotrexate-induced primary cutaneous disffuse large B-cell lymphoma with an " angiocentric" histological morphology. Clin Exp Dermatol 2010, 35:59-62.
50. Shimura C., Satoh T., Takayama K., Yokozeki H. Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis. J Am Acad Dermatol 2009, 61:126-129.
51. Gerli R., Lunardi C., Pitzalis C. Unmasking the anti-inflammatory cytokine response in rheumatoid synovitis. Rheumatol [Oxford] 2002, 41:1341-1345.
52. Paulie S., Ehlin-Henriksson B., Mellstedt H., Koho H., Ben-Aissa H., Perlman P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 1985, 20:23-28.
53. Grewal I., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135.
54. Munroe M.E., Bishop G.A. 2007. A costimulatory function for T cell CD40. J Immnuol 2007, 171:671-682.
55. Schonbeck U., Libby P. The CD4/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001, 58:4-43.
56. Lee H.Y., Jeon H.S., Song E.K., Han M.K., Park S.I., Lee S.I., et al. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis. Arthritis Rheum 2006, 54:1747-1758.
57. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., Routsias J.G. Elevated levels of soluble CD40 ligand [sCD40L] in serum of patients with systemic autoimmune diseases. J Autoimmunity 2006, 26:165-171.
58. Liu M.F., Chao S.C., Wang C.R., Lei H.Y. Expression of CD40 and CD40 lignad among cell populations within rheumatoid synovial compartment. Autoimmunity 2001, 34:107-113.
59. Zheng X., Suzuki M., Ichim T.E., Zhang X., Sun H., Zhu F., et al. Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010, 184:6457-6464.
60. Andreakos E., Rauchhaus U., Stavropoulos A., Endert G., Wendisch V., Benahmed A.S., et al. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 2009, 60:994-1005.
61. Durie F.H., Fava R.A., Foy T.M., Aruffo A., Ledbetter J.A., Noelle R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993, 261:1328-1330.
62. Grammer A.C., Slota R., Fischer R., Gur H., Girschick H., Yarboro C., et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520.
63. Kawai T., Andrews D., Colvin R.B., Sachs D.H., Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000, 6:114.
64. Paterson D.J., Jefferies D.J., Green J.R., Brandon M.R., Corthesy P., Puklavec M., et al. Antigens of activated rat T lymphocytes including a molecule of 50, 000 Mr detected only on CD4+ T blasts. Mol Immunol 1987, 24:1281-1290.
65. So T., Lee S.W., Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev 2008, 19:253-262.
66. Sugumura K., Ishii N., Wienberg A.D. The therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004, 4:420-431.
67. Weinberg A.D. OX40: targeted immunotherapy implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 2002, 23:102-109.
68. Akiba H., Atsuta M., Yagita H., Okumura K.O. Identification of rat OX40 ligand by molecular cloning. Biochem Biophys Res Commun 1998, 251:131-136.
69. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005, 23:23-68.
70. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity. Nat Rev Immunol 2003, 3:600-620.
71. Salek-Ardakani S., Croft M. Regulation of CD4 T cell memory by OX40 [CD134]. Vaccine 2006, 13:872-883.
72. Weinberg A.D., Evans D.E., Thahofer C., Shi T., Prell R.A. The generation of T cell memory: a review describing the molecular and cellular events following OX40 [CD134] engagement. J Leuko Biol 2004, 75:962-972.
73. Gramaglia I., Cooper D., Miner K.T., Kwon B.S., Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000, 165:3043-3050.
74. Maxwell J.R., Weinberg A., Prell R.A., Vella A.T. Danger and OX40 receptor signaling synergizes to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000, 164:107-112.
75. Rogers P.R., Song J., Gramaglia I., Killeen N., Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and essential for long-term survival of CD4+ T cells. Immunity 2001, 164:445-455.
76. Weinberg A.D., Vella A.T., Croft M. OX40: life beyond the effector T cell stage. Sem Immunol 1998, 10:471-480.
77. Weinberg A.D., Wegmann K.W., Funutake C., Whitham R.H. Blocking Ox-40/Ox-40 ligand interaction in vitro and in vivo leads to decreased T-cell function and amelioration of EAE. J Immunol 1999, 162:1818-1826.
78. Semper-Ortells J.M., Perez-Garcia V., Marin-Alberca G., Persis-Pertusa A., Benito J.M., Marco F.M., et al. Identification and phenotype of regulatory T cells in rheumatoid arthritis according to activity score-28. Autoimmunity 2009, 42:636-645.
79. Giacomelli R., Passacantado A., Perricone R., Parzanese I., Rascente M., Minosola M., et al. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. Clin Exp Rheumatol 2001, 19:317-320.
80. Boot E.P., Koning G.A., Storm G., Wagenaar-Hilbers J.P., van Eden W., Everse L.A., et al. CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Res Ther 2005, 7:R604-R615.
81. Passacantando A., Parzanese I., Rascente M., Petrucci C., Minosola G., Tonietti G. Synovial fluid OX40 T lymphocytes of patients with rheumatoid arthritis display Th2/Th0 polarization. Int J Immunopathol Pharmacol 2006, 19:499-505.
82. Yoshioka T., Nakajima A., Akiba H., Ishiwata T., Asano G., Yoshino S., et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000, 30:2815-2823.
83. Saijo S., Asano M., Horai R., Yamamoto H., Iwakura Y. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 2002, 46:533-544.
84. Vinay D.S., Kwon B.S. Genes, transcripts, and proteins of CD137 receptor and ligand. CD137 pathway: immunology and diseases 2006, 1-14. Springer, New York, USA. L. Chen (Ed.).
85. Wilcox R.A., Chapoval A.I., Gorski K.S., Otsuji M., Shin T., Flies D.B., et al. Expression of functional CD137 receptor by dendritic cells. J Immunol 2002, 168:4262-4267.
86. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4[+] CD25[+] immunoregulatory T cells: gene expression analysis reveals a functional role for the glucorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
87. Vinay D.S., Cha K., Kwon B.S. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med 2006, 84:726-736.
88. Jung H.W., Choi S.W., Choi J.I., Kwon B.S. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2004, 36:13-22.
89. Michel J., Langstein J., Hofstadter F., Schwarz H. A soluble form of CD137 [ILA/4-1BB], a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 1998, 28:290-295.
90. Seo S.K., Choi J.H., Kim Y.H., Kang W.J., Park H.Y., Suh J.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004, 10:1088-1094.
91. Kao J.K., Hsu Y.T., Lin C.Y. Role of new population of peripheral CD11c[+] CD8[+] T cells and CD4[+] CD25[+] regulatory T cells during acute and remission stages in rheumatoid arthritis patients. J Microbiol Immunol Infect 2007, 40:419-427.
92. Vinay D.S., Kim C.H., Choi B.K., Kwon B.S. Origins and functional basis of regulatory CD11c+CD8+ T cells. Eur J Immunol 2009, 39:1552-1563.
93. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243.
94. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller M., Falk W., et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305.
95. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody [anti-Fas] to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989, 169:1747-1756.
96. Alderson M.R., Armitage R.J., Maraskovsky E., Tough T.W., Roux E., Schooley K., et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993, 178:2231-2235.
97. Nagata S., Golstein P. The Fas death factor. Science 1995, 267:1449-1456.
98. Fujisawa K., Asahara H., Okamoto H., Aono H., Hasunuma T., Kobata T., et al. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. J Clin Invest 1996, 98:271-278.
99. Tanaka H., Ota K., Ikusaka M., Ejima M., Maruyama S. Expression of Fas-antigen on T cells in multiple sclerosis. Rinsho Shinkeigaku 1995, 35:299-301.
100. Zhang H., Yang Y., Horton J.L., Samoilova E.B., Judge T.A., Turka L.A., et al. Amelioration of collagen-induced arthritis by CD95 [Apo-1/Fas] -ligand gene transfer. J Clin Invest 1997, 100:1951-1957.
101. Owani-Kawabata N., Takai-Imamura M., Katsuta O., Nakamura H., Nishioka K., Funahashi K., et al. ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Dis 2010, 11:221-231.
102. Ogawa Y., Ohtsuki M., Uzuki M., Sawai T., Onozawa Y., Nakayama J., et al. Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. Arthritis Rheum 2003, 48:3350-3358.
103. Nishimura-Morito Y., Nose M., Inoue T., Yonehara S. Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. Int Immunol 1997, 9:1793-1799.
104. Bremer E., Abduahad W.H., de Bryun M., Samplonius D.F., Kallenberg C.G., Ambrust W., et al. Selective elimination of pathogenic synivial fluid T-cell- from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling. Immunol Lett 2011, 138:161-168.
105. Lundy S.K., Fox D.A. Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. Arthritis Res Ther 2009, 11:R128.
106. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690.
107. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
108. Sedger L.M., Shows D.M., Blanton R.A., Peshcon J.J., Goodwin R.G., Cosman D., et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999, 163:920-926.
109. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999, 189:1343-1354.
110. Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand [TRAIL]. J Exp Med 1999, 190:1155-1164.
111. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., Perussia B. Natural killer [NK] cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1989, 188:2375-2380.
112. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons [IFNs] regulate tumor necrosis factor-related apoptosis-inducing ligand [TRAIL] expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999, 189:1451-1460.
113. Kayagaki N., Yamaguchi N., Nakayama M., Kawasaki A., Akiba H., Okumura K. Involvement of TNF related apoptosis-inducing ligand in human CD4+ T cell mediated cytotoxicity. J Immunol 1999, 162:2639-2647.
114. Thomas W.D., Hersey P. TNF-related apoptosis-inducing ligand [TRAIL] induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998, 161:2195-2200.
115. Nieda M., Nicol A., Koezuka Y., Kikuchi A., Lapteva N., Tanaka Y., et al. TRAIL expression by activated human CD4[+] V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001, 97:2067-2074.
116. Kayagaki N., Yamaguchi N., Nakayama M., Takeda K., Akiba H., Tsutsui H., et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999, 163:1906-1913.
117. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., et al. Tumor necrosis factor-related apoptosis-inducing ligand [TRAIL] contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001, 193:661-670.
118. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001, 7:94-100.
119. Degli-Esposti M. To die or not to die - the quest of the TRAIL receptors. J Leukobiol 1999, 65:535-542.
120. de Vries E.G., Gietema J.A., de Jong S. Tumor necrosis factor-related apoptosis inducing ligand pathway and its therapeutic implications. Clin Cancer Res 2006, 12:2390-2393.
121. Wang S., El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003, 22:8628-8633.
122. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., et al. Tumor necrosis factor-related apoptosis-inducing ligand [TRAIL] is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000, 191:1095-1104.
123. Yao Q., Wang S., Gambotto A., Glorioso J.C., Evas C.H., Robbins P.D., et al. Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther 2003, 10:1055-1060.
124. Yao Q., Seol D.W., Mi Z., Robbins P.D. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res Ther 2006, 8:R16.
125. -/- mice. Nat Immunol 2003, 4:255-260.
126. Liu Z., Xu X., Hsu H.C., Tousson A., Yang P.A., Wu Q., et al. CII-DC-AdTRAIL cells gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 2003, 112:1332-1341.
127. Ichikawa K., Liu W., Fleck M., Zhang H., Zhao L., Ohtsuka T., et al. TRAIL-R2 [DR5] mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003, 171:1061-1069.
128. Tracey K.J., Cerami A. Tumor necrosis factor: a plieotropic cytokine and therapeutic target. Annu Rev Med 1994, 145:491-503.
129. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have learned?. Annu Rev Immunol 2001, 19:163-196.
130. Apostolaki M., Armaka M., Victoratos P., Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. TNF pathophysiology. Molecular and cellular mechanisms 2010, vol. 11:1-26. Karger, Basel, Switzerland. G. Kollias, P.P. Sfikakis (Eds.).
131. Brakebusch C., Nophar Y., Kemper O., Engelmann H., Wallach D. Cytoplasmic truncation of the p55 tumour necrosis factor [TNF] receptor abolishes signalling, but not induced shedding of the receptor. EMBOJ 1992, 11:943-950.
132. Mackay F., Loetscher H., Stueber D., Gehr G., Lesslauer W. Tumor necrosis factor alpha [TNF-alpha] -induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 1993, 177:1277-1286.
133. Tartaglia L.A., Weber R.F., Figar I.S., Reynolds C., Palladino M.A., Goeddel D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Nat Acad Sci USA 1991, 88:9292-9296.
134. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
135. Li P., Schwarz E.M. The TNF-alpha transgenic mouse model of inflammatory arthritis. Sem Immunopathol 2003, 25:19-33.
136. Mori L., Iselin S., De Libero G., Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 [TNFR1] -IgG1-treated and TNFR1-deficient mice. J Immunol 1996, 157:3178-3182.
137. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human necrosis factor: a predictive genetic model of arthritis. EMBOJ 1991, 10:4025-4031.
138. Kollias G., Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002, 13:315-321.
139. Williams-Skip C., Raman T., Valuck R.J., Watkins H., Palmer B.E., Scheinman R.I. Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model. Arthritis Rheum 2009, 60:408-418.
140. Schneider P.P., Mackay F., Steiner V., Hofmann K., Bodmer J.L., Holler N. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1759.
141. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
142. Shu H.B., Hu W.H., Johnson H. TALL-1 is a novel member of the tumor necrosis family that is downregulated by mitogens. J Leukobiol 1999, 65:680-683.
143. Craxton A., Magaletti D., Ryan E.J., Clark E.A. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003, 101:4464-4471.
144. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
145. Shulga-Morskaya S., Dobles M., Walsh M.E., Ng L.G., Mackay F., Rao S.P. B cell-activated factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004, 173:2331-2341.
146. Thompson J.S., Bixler S.A., Qian E., Vora K., Scott M.L., Cachero T.G. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001, 293:2108-2111.
147. Yan M., Brady J.R., Chan B., Lee W.P., Hsu B., Harless S. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Current Biol 2001, 11:1547-1552.
148. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
149. Sun J., Lin Z., Feng J., Li Y., Shen B. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur J Pharmacol 2008, 597:1-5.
150. Mackay F., Browning J.L. BAFF: a fundamental survival for B cells. Nat Rev Immunol 2002, 2:465-475.
151. Townsend M.J., Monroe J.G., Chan A.C. B-cell targeted therapies in human autoimmune diseases: an update perspective. Immunol Rev 2010, 237:264-283.
152. Moura R.A., Cascao R., Perpetuo I., Canhao H., Viera-Sousa E., Moura A.F. Cytokine pattern in early rheumatoid arthritis favors B-cell activation and survival. Rheumatol [Oxford] 2011, 50:278-282.
153. Zhang M., Ko K.H., Lam Q.L., Lo C.K., Srivastava G., Zheng B., et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 2005, 17:1081-1092.
154. Badr G., Borhis G., Lefevre E.A., Chaoul N., Deshayes F., Dessirier V., et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 2008, 111:2744-2754.
155. Woo Y.J., Yoon B.Y., Jhun J.Y., Oh H.J., Min S., Cho M.L., et al. Regulation of B cell activating factor belonging to the TNF family [BAFF] receptor expression by NF-kB signaling in rheumatoid arthritis B cells. Exp Mol Med 2011, 43:350-357.
156. Izumi Y., Komori A., Yasunaga Y., Hashimoto S., Miyashita T., Abiru S., et al. Rheumatoid arthritis following a treatment with IFN-alpha/Ribavarin against HCV infection. Internal Med 2011, 50:1065-1068.
157. Benucci M., Manfredi M., Puttini P.S., Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?. Autoimmunity Rev 2010, 9:801-813.
158. Belimumab: anti-BLyS human monoclonal antibody anti-BLyS, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs RD 2008, 9:197-202. Anonymous.
159. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic Mircetic.V., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase 1b, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72.
160. Lai Kwan Lam Q., King Hung Ko O., Zheng B.J., Lu L. Local BAFF gene silencing suppresses TH17-cell generation and ameliorates autoimmune arthritis. Proc Nat Acad Sci USA 2008, 105:14993-14998.